Aesica Pharmaceuticals S.r.I. collaborates with QAD to meet China's Food and Drug Administration's shortened serialisation deadline
The new system was implemented within three months
23 June 2014 – Aesica Pharmaceuticals S.r.l, the Italian division of Aesica, the global pharmaceutical contract development and manufacturing organisation (CDMO), has today announced the launch of a QAD integrated serialisation system to comply with change from China's Food and Drug Administration (CFDA) at its site in Pianezza. The new requirements brought forward by CFDA drastically cut the serialisation implementation deadline to just three months from its original 12 month timeline.
In partnership with QAD - the leading provider of enterprise software solutions - Aesica was able to implement a new solution that assured serialisation compliance for two pharmaceutical products for the Chinese market. The company site demonstrated the ability to quickly react to unexpected changes within this regional regulatory landscape.
The new requirements are designed to maintain customer safety, whilst fighting drug counterfeiting, streamlining the recall process and minimising financial loss. Primarily it involved upgrading and utilising a newly created serialisation module developed in QAD Enterprise Applications. This module, which was specifically developed to meet the new serialisation regulations, allows Aesica Pharmaceuticals S.r.I. to identify individual packaging down to the smallest sellable unit sizes and aggregate individual unit serial numbers as packages are bundled, boxed and placed on shipping pallets. Aesica Pianezza can seamlessly track and trace each single pack of medication and report serial numbers to the required Government Agencies for a small number of products once they have been produced and imported.
QAD's research and development team worked directly with Aesica's Information Technology group to bring the new serialisation module to fruition. In addition, Aesica has developed a new Enterprise Financials module serving as a complete all-in-one solution for multiple financial requirements and procedures. This module significantly reduces the number of applications in use, achieving the goal of covering all business processes in one complete Enterprise Resource Planning (ERP) solution.
Maurizio Beninati, IT Manager Italy at Aesica Pharmaceuticals S.r.I., commented: "Major changes are happening in product serialisation and tracking regulations across pharmaceutical markets worldwide and China is a prime example of this. The ability to respond swiftly to adjust practices and processes to meet these challenges head on is pivotal to success in this fiercely competitive environment. QAD has proven to be a great strategic partner in the rush to meet such a hugely accelerated deadline from the CFDA. By combining our respective skills and expertise, we conquered this challenge in full."
Bhavesh Kotecha, Corporate Services Director at Aesica, added: "At Pianezza we work with pharmaceutical companies to manufacture products for the Chinese market, and we are pleased to have worked closely with QAD to ensure a secure product line for the two pharmaceutical products. The strategic decision to keep and upgrade QAD as the ERP system at our Italian facility has proved to have been a highly successful choice. The solution is now in place to meet the requirements and regulations of the Chinese pharmaceutical market, establishing the scale of our ability to react and adapt quickly to challenging situations."
Aesica supplies contract development and contract manufacturing services for finished products and active pharmaceutical ingredients to a host of the world's leading pharmaceutical companies and emerging biotechnology organisations.
· Aesica is one of the UK's fastest growing companiesand over the last five years has more than trebled its turnover.
· The company currently employs approximately 1,300 people.
· In addition to its headquarters in Newcastle upon Tyne, UK, Aesica has development and manufacturing sites across Europe including Cramlington, Nottingham and Queenborough in the UK, Monheim and Zwickau in Germany and Pianezza in Italy.
· The vision of Aesica is to become the number one supplier of APIs and formulated products to the pharmaceutical industry.
· Aesica is a portfolio company of Silverfleet Capital, one of the leading European mid-market private equity firms, which invested in the business in October 2011.
For media enquiries, please contact Tristan Jervis or Alex Heeley on: +44 (0) 207 203 6740 or e-mail:[email protected].